Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30866995 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3PARP10MAPT | |
| SCHEMBL30381016 | 0.84 | PARP10 (0.56) | SLC6A2SLC6A4SLC6A3PARP10MAPT | |
| SCHEMBL3034825 | 0.84 | PARP10 (0.56) | SLC6A2SLC6A4SLC6A3PARP10MAPT | |
| SCHEMBL7732234 | 0.82 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3PARP10HTR1A | |
| SCHEMBL25981314 | 0.81 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3PARP10MAPT | |
| SCHEMBL19150659 | 0.81 | ALDH1A1 (0.52) | SLC6A2SLC6A4SLC6A3MAPTALDH1A1 | |
| SCHEMBL13857891 | 0.81 | NCOA1 (0.49) | SLC6A2SLC6A4SLC6A3PARP10MAPT | |
| SCHEMBL18181866 | 0.81 | SLC6A4 (0.45) | SLC6A2SLC6A4SLC6A3PARP10MAPT | |
| SCHEMBL15516803 | 0.81 | PARP10 (0.41) | SLC6A2SLC6A4SLC6A3PARP10HTR1A | |
| SCHEMBL8121745 | 0.79 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3PARP10HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-113149983-B | Tyrosine kinase inhibitors | 普林斯匹亚生物制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4112618-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3912979-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-113149983-A | Tyrosine kinase inhibitors | 普林斯匹亚生物制药公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-10 | — | — | US | disclosed |
| CN-106459049-B | Tyrosine kinase inhibitors | 普林斯匹亚生物制药公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3303334-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2016196840-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | SLC6A2 4837/4885SLC6A4 4851/4885SLC6A3 4822/4885 |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | SLC6A2 4837/4885SLC6A4 4851/4885SLC6A3 4822/4885 |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | SLC6A2 4837/4885SLC6A4 4851/4885SLC6A3 4822/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | SLC6A2 4837/4885SLC6A4 4851/4885SLC6A3 4822/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | SLC6A2 4837/4885SLC6A4 4851/4885SLC6A3 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.